Shots:

• Bayer collaborates with Roche to develop & commercialize NGS-based companion diagnostics for multiple cancer therapies developed by Bayer and covers FMI’s complete portfolio of tests including its Foundation One CDx
• The companies initiate the collaboration with development of CDx of Vitraki (larotrectinib)- a first TRK inhibitor for TRK fusion cancer in all solid tumors- approved in the US
• FoundationOne CDx is a sequencing-based in vitro diagnostic device- identify patients benefitted from targeted therapies with their approved therapeutic product labeling and has received FDA’s approval for all solid tumors

Click here to read full press release/ article

Ref: Bayer | Image: Roche